SCHEMBL6531320

SCHEMBL6531320

COc1ccc(Cc2nc(Nc3cccc(F)c3)nc(N[C@H](CO)CC(C)C)n2)cc1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
IDH2 P48735 2/20 0.44
KCNH3 Q9ULD8 8/20 0.43
CDK1 P06493 1/20 0.43
KDM4E B2RXH2 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPT P10636 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
GBA1 P04062 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
APP P05067 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6531002 0.88 ALDH1A1 (0.49) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6528805 0.86 CYP2C9 (0.44) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL8298689 0.86 CYP2C9 (0.44) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6527570 0.85 IDH2 (0.43) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6530404 0.85 IDH2 (0.43) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6531883 0.79 KCNH3 (0.52) IDH2KCNH3KDM4ENPSR1MAPT
SCHEMBL8298690 0.78 APP (0.54) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6530549 0.78 MAPT (0.54) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6529618 0.77 KCNH3 (0.45) ALDH1A1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6529521 0.76 IDH2 (0.47) IDH2KCNH3KDM4ENPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO claimed
WO-2005003103-A2 2, 4, 6-TRI-SUBSTITUTED 6-MEMBERED HETEROCYCLES AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES ASTRAZENECA AB (SE) 2005-01-13 WO disclosed